A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)

Sponsor
NYU Langone Health (Other)
Overall Status
Completed
CT.gov ID
NCT02723097
Collaborator
(none)
20
1
1
19.4
1

Study Details

Study Description

Brief Summary

The objective of this protocol is to test the feasibility and acceptability of the Relaxation Response Resiliency Program (3RP), a psychotherapy treatment providing a variety of mind body skills and interventions to decrease medical and mental health symptoms and build resilience, in Spanish-speaking World Trade Center (WTC) survivors, and to examine its clinical effectiveness to reduce Post Traumatic Stress Disorder (PTSD), depression, anxiety, and lower respiratory symptoms (LRS) and improve psychosocial functioning.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: 3 RP
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)
Actual Study Start Date :
Mar 1, 2016
Actual Primary Completion Date :
Oct 11, 2017
Actual Study Completion Date :
Oct 11, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Relaxation Response Resiliency Program (3RP)

Behavioral: 3 RP
Other Names:
  • Relaxation Response Resiliency Program
  • Outcome Measures

    Primary Outcome Measures

    1. Structured Clinical Interview (SCID-NP) for Diagnostic and Statistical Manual DSM-IV [1 Month]

      State-of-the-art instrument for obtaining psychiatric diagnoses.

    2. Symptom Severity using PTSD Checklist [1 Month]

      Symptoms will be assessed with the PTSD Checklist (PCL), a 17-item self-report measure of current (past month) PTSD symptoms based on the DSM-IV criteria. It is a widely-used and validated measure of PTSD symptom severity.

    3. Assessment of Anxiety Symptoms using Generalized Anxiety Disorder Scale (GAD-7) [1 Month]

    4. Measure of Functional Impairment using the Range of Impaired Functioning Tool (RIFT) [1 Month]

      widely-used instrument that taps the domains of work, household duties, interpersonal relationships, recreation, and subjective satisfaction with life. Each domain is rated on a five-point scale from very good to very poor. The total score is the sum of the different domains.

    5. Assessment of Mindful attention using Mindful Attention Awareness Scale (MAAS) [1 Month]

      The MAAS is a 15-item questionnaire on which respondents indicate, on a 6 point Likert-type scale (1 = almost always to 6 = almost never), their level of awareness and attention to present events and experiences.

    6. Health Promoting Behaviors will be assessed with the Health Promoting Lifestyles Profile-II (HPLP-II) [1 Month]

      he HPLP-II is a 52 item self-report inventory of health behaviors and has been used in previous mind-body treatment studies

    7. Measure of treatment expectancy using the Treatment Credibility/Expectancy Questionnaire. [1 Month]

      The 6-item Treatment Credibility/Expectancy Questionnaire (CEQ)84 will be used to examine treatment expectancy related to the 3RP.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • score > or = 44 on the PTSD Checklist PCL, considered the broad definition of PTSD syndrome71

    • report at least one LRS symptoms (i.e., shortness of breath, wheezing, dyspnea or cough).

    • Spanish Speaking

    Exclusion Criteria:
    • regular practice of eliciting relaxation response (i.e., meditation, yoga) in the past 6 months,

    • serious unmanaged mental illness including bipolar disorder, psychosis, and active substance misuse disorders;

    • inability to participate in consecutive sessions over 3-month period.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 New York University School of Medicine New York New York United States 10016

    Sponsors and Collaborators

    • NYU Langone Health

    Investigators

    • Principal Investigator: Lucia Ferri, MD, New York University Medical School

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    NYU Langone Health
    ClinicalTrials.gov Identifier:
    NCT02723097
    Other Study ID Numbers:
    • 15-00721
    First Posted:
    Mar 30, 2016
    Last Update Posted:
    Oct 18, 2017
    Last Verified:
    Oct 1, 2017

    Study Results

    No Results Posted as of Oct 18, 2017